// App-Quantinova.ai

OP0250 : EFFICACY AND SAFETY OF ROMILKIMAB IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 24-WEEK, PROOF OF CONCEPT STUDY

Researchers

Presenter

  • Y. Allanore

Principal Investigators

  • P. Wung

  • C. Soubrane

  • C. Esperet

  • M. Frederic

  • R. Bejuit

  • A. Lahmar

  • D. Khanna

  • C. Denton

Medical Centers

  • Cochin Hospital, Rheumatology B, Paris, France,

  • Sanofi US, Bridgewater, United States of America

  • Sanofi, Chilly-Mazarin, France

  • University of Michigan - Ann Arbor - United States of America

  • Kings College London, London, United Kingdom

Locations

  • France

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Scleroderma

  • Mental retardation, X-linked, syndromic, 15

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02921971

Sponsors

  • Inventiva

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved